[Guidelines for good practice: anti-ulcer agents, indications in the adult. French Agency for Health Safety of Health Products].
D000328:Adult; D000368:Aged; D000863:Antacids / Q000627:therapeutic use; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000517:prevention & control; D004940:Esophageal Stenosis / Q000209:etiology / Q000517:prevention & control; D004941:Esophagitis / Q000188:drug therapy; D005756:Gastritis / Q000150:complications / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000517:prevention & control; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000627:therapeutic use
D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D011899:Ranitidine